Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Dermatology and Therapy|July 15, 2025
Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic DermatitisEmma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, et al.The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.The Journal of Dermatological Treatment|March 12, 2026
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitisJonathan I Silverberg, Thomas Bieber, Kilian Eyerich, et al.Journal of Medicinal Chemistry|March 12, 2009
Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat modelsFelix M Rivas, James P Stables, Lauren Murphree, et al.Dermatology and Therapy|June 15, 2023
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 StudyAmy S Paller, Carsten Flohr, Lawrence F Eichenfield, et al.The British Journal of Dermatology|March 30, 2023
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsAndrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, et al.Alzheimer'S & Dementia (New York, N. Y.)|March 10, 2026
Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's diseasePaul Ardayfio, Garrett R Mullins, Rashna Khanna, et al.Pageof 4